ACADIA Pharma (ACAD): Rasio rega marang dodolan
Stable cash flow from neurological drug sales fully covers R&D investments, ensuring liquidity for ACADIA Pharmaceuticals (ACAD). This historical P/S chart reflects the business valuation dynamics relative to revenue, where the metric settled at 2.60. Efficiency gains are driven by AI-powered drug discovery automation, while niche market resilience is supported by in-house drug manufacturing in the US.
%20Multiplikator%20P%2FS&width=1200&height=400&colorIndex=0&v=mwejrfjc.e5f-7d7lczk&start=20220704&end=20261113&filename=GURU_Markets_-_ACAD_-_ACADIA-Pharmaceuticals_-_PS-Multiple "ACAD - Rasio kapitalisasi pasar marang pendapatan ACADIA Corp ing rentang 04.07.2022 - 13.11.2026 | 👁️GURU.Markets👁️")
Rincian metrik lan analitis perusahaan ACADIA Pharmaceuticals Inc (ACAD)
- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi bursa:
- indikator nilai aset resik miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Kabeh Utang marang Dana Pribadi ACADIA Pharmaceuticals|ACAD - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas ACADIA Corp|ACAD - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku ACADIA Pharmaceuticals Inc|ACAD - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan ACADIA Pharmaceuticals|Likuiditas darurat acadia-pharm.com
- informasi bathi lan kelipatan valuasi:
ACAD - Penghasilan resik|Proyeksi bathi mangsa ngarep ACADIA Pharmaceuticals|ACAD - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep ACADIA Pharma|ACAD - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan ACADIA Pharmaceuticals Inc|ACAD - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan ACADIA Pharmaceuticals|ACAD - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan acadia-pharm.com|ACAD - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep ACADIA Pharmaceuticals
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:ACAD acadia-pharm.com
The P/S ratio determines the market value of a business relative to its annual sales volume, allowing for an assessment of whether an asset is overpriced prior to the publication of financial statements. By analyzing the P/S level of ACADIA Pharmaceuticals (ACAD), an investor compares market capitalization with the distribution efficiency of neuropsychiatric drugs, where logistics optimization directly impacts revenue and justifies the current stock market value.
Perusahaan pesaing
BIIB (biogen.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Neurocrine Biosciences, Inc. NBIX|RGC (Regencell Bioscience Ltd) - Rasio rega marang dodolan|Axsome Therapeutics Inc - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan XENE (Xenon Corp)|VKTX: Multiplikator P/S|supernus.com (SUPN) - Multiplikator P/S|Rasio rega marang pendapatan Catalyst Pharmaceuticals, Inc.|DNLI: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Harmony Pharma (HRMY)|Kapitalisasi marang pendapatan Biohaven Corp BHVN|Multiplikator P/S AMLX (Amylyx Pharmaceuticals)|Multiplikator P/S trevitherapeutics.com TRVI|Praxis Precision Medicines, Inc. - Multiplikator P/S|Anavex (AVXL) - Kapitalisasi marang pendapatan|CBLL: Multiplikator P/S|Rega marang dodolan Prothena Corp (PRTA)|Kapitalisasi marang pendapatan ALEC|Multiplikator P/S annexonbio.com|Kapitalisasi marang pendapatan OMER (Omeros Corporation)|Kapitalisasi marang volume dodolan NGNE|Multiplikator P/S ACIU (AC Immune Corp)|Koefisien rega marang pendapatan Voyager Corp (VYGR)|Neumora Therapeutics - Multiplikator P/S|scilexholding.com (SCLX) - Kapitalisasi marang pendapatan|TVGN: Multiplikator P/S|Alpha Cognition Inc. (ACOG) - Multiplikator P/S|Rasio rega marang pendapatan Cognition Therapeutics, Inc.|Rasio rega marang pendapatan IKT|Rasio rega marang pendapatan Cassava Sciences, Inc. (SAVA)|Koefisien rega marang pendapatan assertiotx.com|Multiplikator P/S COYA (Coya Therapeutics)|Multiplikator P/S VistaGen Therapeutics, Inc. VTGN|Ovid Rx - Multiplikator P/S|Acumen Pharmaceuticals, Inc (ABOS) - Kapitalisasi marang pendapatan|CRVO: Multiplikator P/S|Alterity Therapeutics Limited (ATHE) - Multiplikator P/S|CLNN (Clene Inc) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan PEPG (PepGen Corp)|Rasio rega marang pendapatan Jupiter Neurosciences (JUNS)|Relmada Corp - Rasio kapitalisasi marang pendapatan|Multiplikator P/S ANVS (Annovis Bio, Inc.)|Grace Therapeutics Inc (GRCE) - Rega marang dodolan|AIFF: Kapitalisasi marang pendapatan|KLTO - Multiplikator P/S|neurosense-tx.com (NRSN) - Rasio rega marang pendapatan|Reviva Pharmaceuticals, Inc. - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan MetaVia Inc.|Rega marang dodolan neuraxis.com NRXS|Multiplikator P/S HSDT|Multiplikator P/S passagebio.com (PASG)|Multiplikator P/S NEUP (Neuphoria Therapeutics)|NERV - Kapitalisasi marang pendapatan|Athira Pharma, Inc. - Multiplikator P/S|ADXN - Multiplikator P/S|ALZN: Multiplikator P/S|Rasio kapitalisasi marang pendapatan CYCN|PTIX (Protagenic Therapeutics Inc.) - Multiplikator P/S|Pasithea (KTTA) - Koefisien rega marang pendapatan|Multiplikator P/S CRGT|Multiplikator P/S avenuetx.com (ATXI)|BrainStorm Cell Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan CARA|CHRO - Rasio rega marang pendapatan|Rasio rega marang dodolan ELYM|ITCI: Multiplikator P/S|longboardpharma.com - Rasio kapitalisasi pasar marang pendapatan|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|Multiplikator P/S NKGen Biotech Inc|Rasio rega marang pendapatan NeuroBo (NRBO)|SAGE (Sage Therapeutics Inc) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|TRVN - Kapitalisasi marang pendapatan|Vigil Neuro - Multiplikator P/S|WENA - Multiplikator P/S|CERE: Multiplikator P/S
